All In Biotech

Drug Trial Radar · NCT07374848

Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors

An Open-label, Phase 1a/b, Multicenter Study of ZL-6201 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy in Participants With Sarcoma and Selected Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Mar 2, 2026

Primary completion

Aug 2028

Study completion Sep 2029

Sponsor

Lead sponsor
Zai Lab (Shanghai) Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Zai Lab (US) LLC
First posted
Jan 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and tolerability of investigational study drug ZL-6201 for treating sarcoma and solid tumors cancer.

Conditions

  • Solid Tumors
  • Sarcomas

Interventions

  • ZL-6201Drug

    ZL-6201 as a single-agent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Dose Limiting ToxicitiesTime frame: 1 cycle of study treatment (each cycle is 21 days)
  2. Incidence of Treatment Emergent Adverse EventsTime frame: 36 months
  3. Incidence of Serious adverse eventsTime frame: 36 months
  4. Number of participants with clinical laboratory abnormalitiesTime frame: 36 months
  5. Number of participants with vital sign abnormalitiesTime frame: 36 months
  6. Number of participants with electrocardiogram (ECG) abnormalitiesTime frame: 36 months

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • USC Norris Cancer Hospital

    Los Angeles, California · Recruiting

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Florida Cancer Specialist

    Sarasota, Florida · Recruiting

  • Washington University in St. Louis

    St Louis, Missouri · Recruiting

  • Memorial Sloan-Kettering Cancer Center

    Long Island City, New York · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanghai Sixth People's Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.